

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS O. Dox 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DA	TE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO. ABI1150-18 5713	
09/628,387	08/01/200	00	Patrick Soon-Shiong		
30542	7590 06	5/09/2003			
FOLEY & 1		EXAMINER			
P.O. BOX 80278 SAN DIEGO, CA '92138-0278			PULLIAM, AMY E		
		•		ART UNIT	PAPER NUMBER
				1615	15
				DATE MAILED: 06/09/2003	()

Please find below and/or attached an Office communication concerning this application or proceeding.

,	·		
	Application No.	Applicant(s)	
Advisory Action	09/628,387	SOON-SHIONG ET AL.	
	Examin r	Art Unit	
	Amy E Pulliam	1615	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondenc address	
THE REPLY FILED 09 May 2003 FAILS TO PLACE TH Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appearamination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applic) a timely filed amendment whi	cation. A proper reply to a children ch	
PERIOD FOR RE	PLY [check either a) or b)]		
a) The period for reply expires 3_months from the mailing date of b) The period for reply expires on: (1) the mailing date of this Adv event, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The dath have been filed is the date for purposes of determining the period of extens 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three moleaned patent term adjustment. See 37 CFR 1.704(b).	isory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date of FILED WITHIN TWO MONTHS OF THE te on which the petition under 37 CFR 1.1 sion and the corresponding amount of the statutory period for reply originally set in	the final rejection. FINAL REJECTION. See MPEP 36(a) and the appropriate extension fee fee. The appropriate extension fee unde the final Office action; or (2) as set forth i	er in
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CF			
2. The proposed amendment(s) will not be entered be	ecause:		
(a) X they raise new issues that would require further	er consideration and/or search (see NOTE below);	
(b) they raise the issue of new matter (see Note b	pelow);		
 (c) they are not deemed to place the application issues for appeal; and/or 	n better form for appeal by mat	erially reducing or simplifying the	he
(d) they present additional claims without cancel	ing a corresponding number of	inally rejected claims.	
NOTE: See Continuation Sheet.			
3. Applicant's reply has overcome the following reject	tion(s):		
 Newly proposed or amended claim(s) would canceling the non-allowable claim(s). 	be allowable if submitted in a s	eparate, timely filed amendmen	nt
5. The a) affidavit, b) exhibit, or c) request fo application in condition for allowance because:		idered but does NOT place the	
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly	
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: <u>1-16, 30-44, 58-78, 98-101, 104-11, 149-151, 153-158, 160-162, 164-177.</u>	07, 110-113, 116-119, 122-125, 12	<u>8-131, 133-135, 137-141, 145-147</u>	, <u>.</u>
Claim(s) withdrawn from consideration:			
8. The proposed drawing correction filed on is	a) approved or b) disapp	proved by the Examiner.	
9. Note the attached Information Disclosure Statemen			
10. Other:			

Continuation of 2. NOTE: Applicant has amended the claims to include the new limitations, "cremophor-free" and "wherein the cycle time between adminstrations of said total dose is less than about three weeks." Neither of these limitations were present in the claims prior to this amendment., and therefore, neither of these limitations have been previously considered.

THURMAN K. PAGE SUPERVISORY PATENT EXAMINER TECHNOLOGY CHNTER 1600